Inimmune has developed a family of next generation TLR agonists designed for optimal safety, activity, delivery, and stability. Our novel compounds are designed to target specific innate immune pathways to reprogram the immune system and drive a therapeutic response. Our clinical focus is developing INI-2004, a TLR4 agonist, into a novel, safe, and effective immunotherapy to treat allergic disease. We are building INI-2004 as a “pipeline in a product” to treat seasonal and perennial allergic rhinitis, food allergies and allergic asthma. We have successfully completed a Phase I trial with INI-2004 for seasonal allergic rhinitis and have advanced into a Phase II clinical trial based on the strength of the Phase I data. We also have an ongoing Phase I trial with INI-4001, a TLR7/8 agonist, to treat solid tumors that will be completed in the second half of 2026.
Inimmune has completed a Phase I clinical trial evaluating the safety and tolerability of INI-2004 (a TLR4 agonist) as a treatment for allergic rhinitis. NCT06038279
Based on the promising data from our Phase I allergy trial we have advanced INI-2004 to a Phase II environmental exposure chamber trial in moderate to severe allergic rhinitis patients. NCT07556393
Inimmune also has an ongoing Phase I clinical trial evaluating the safety and tolerability of INI-4001 (a TLR7/8 agonist) as a cancer treatment. NCT06302426
